Further iterations of the guidelines were published in 1993,6 2001,7 and 2005.8 In 2007 and 2009, focused updates to the guideline were published to expeditiously address new study results and recent changes in the field of interventional cardiology.9,10 The 2009 focused update is notable in that there was direct collaboration between the writing commit- tees for the STEMI guidelines and the PCI guidelines, resulting in a single publication of focused updates on STEMI The evolution of the PCI guideline reflects the growth of knowledge in the field and parallels the many advances and innovations in the field of interventional cardiology, includ- ing primary PCI, BMS and DES, intravascular ultrasound (IVUS) and physiologic assessments of stenosis, and newer antiplatelet and anticoagulant therapies. The 2011 iteration of the guideline continues this process, addressing ethical as- pects of PCI, vascular access considerations, CAD revascu- larization including hybrid revascularization, revasculariza- tion before noncardiac surgery, optical coherence tomography, advanced hemodynamic support devices, no- reflow therapies, and vascular closure devices. Most of this document is organized according to patient flow, consisting of preprocedural considerations, procedural considerations, and postprocedural considerations. In a major undertaking, the STEMI, PCI, and coronary artery bypass graft (CABG) surgery guidelines were written concurrently, with additional collaboration with the SIHD guideline writing committee, allowing greater collaboration between the different writing committees on topics such as PCI in STEMI and revascular- ization strategies in patients with CAD (including unpro- tected left main PCI, multivessel disease revascularization, and hybrid procedures). In accordance with direction from the Task Force and feedback from readers, in this iteration of the guideline, the text has been shortened, with an emphasis on summary Levine et al 2011 ACCF/AHA/SCAI PCI Guideline e579 statements rather than detailed discussion of numerous indi- vidual trials. 